Home / Market News / $CRBU

$CRBU news and market catalysts

The 9 most recent market catalysts affecting $CRBU, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 5 high impact 0 bullish 9 bearish Biotechnology
Nov 6, 2026 Corporate Catalyst Bearish Impact 95
Caribou Biosciences Reports Third Quarter 2026 Financial Results
Caribou Biosciences reported a GAAP net loss of $26.6 million for Q3 2026, a slight improvement from the prior year, but revenue declined. The most critical disclosure is the plann…
Oct 8, 2026 Corporate Catalyst Bearish Impact 55
HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral
HC Wainwright & Co. analyst Robert Burns downgraded Caribou Biosciences (CRBU) from a 'Buy' rating to 'Neutral'. This change in rating suggests that the analyst sees less upside po…
Oct 7, 2026 Corporate Catalyst Bearish Impact 55
Brookline Capital Downgrades Caribou Biosciences to Hold
Brookline Capital's downgrade of Caribou Biosciences from 'Buy' to 'Hold' indicates a shift in the analyst's perception of the company's investment potential. While the specific re…
Oct 7, 2026 Corporate Catalyst Bearish Impact 75
RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1
RBC Capital's downgrade of Caribou Biosciences (CRBU) from Outperform to Sector Perform, coupled with a dramatic price target reduction from $10 to $1, signals a significant loss o…
Oct 7, 2026 Corporate Catalyst Bearish Impact 75
Leerink Partners Downgrades Caribou Biosciences to Market Perform, Lowers Price Target to $1
Leerink Partners analyst Daina Graybosch downgraded Caribou Biosciences (CRBU) from an 'Outperform' rating to 'Market Perform' and drastically cut the price target from $4 to $1. T…
Oct 7, 2026 Corporate Catalyst Bearish Impact 85
Caribou Biosciences shares are trading lower after the company announced it is exploring strategic alternatives.
The announcement that Caribou Biosciences is exploring strategic alternatives is a significant corporate catalyst. This often implies the company is considering options like a sale…
Oct 7, 2026 Corporate Catalyst Bearish Impact 95
Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why
Caribou Biosciences' decision to discontinue its two lead cell therapy programs, vispa-cel and CB-011, is a major negative catalyst for the company. This move, coupled with the exp…
Oct 6, 2026 Corporate Catalyst Bearish Impact 85
Caribou Biosciences shares are trading lower after the company announced it is exploring strategic alternatives.
The announcement that Caribou Biosciences is exploring strategic alternatives is a significant corporate catalyst. This phrase often indicates a company is considering options rang…
Oct 6, 2026 Corporate Catalyst Bearish Impact 85
Caribou Biosciences Announces Strategic Alternatives Review, Discontinues Vispa-Cel And CB-011 CAR-T Programs, Cuts Workforce; Had $113.8M Cash At June 30
The discontinuation of two key CAR-T programs (Vispa-Cel and CB-011) and a workforce reduction are major negative catalysts for Caribou Biosciences. This indicates a failure in the…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.